The stock of Novavax, Inc. (NVAX) has gone down by -8.17% for the week, with a -6.22% drop in the past month and a -29.00% drop in the past quarter. The volatility ratio for the week is 5.11%, and the volatility levels for the past 30 days are 6.48% for NVAX. The simple moving average for the last 20 days is -12.20% for NVAX’s stock, with a simple moving average of -26.01% for the last 200 days.
Is It Worth Investing in Novavax, Inc. (NASDAQ: NVAX) Right Now?
while the 36-month beta value is 1.61.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 1 as “sell.”
The average price point forecasted by analysts for Novavax, Inc. (NVAX) is $20.20, which is $14.47 above the current market price. The public float for NVAX is 110.21M, and currently, short sellers hold a 40.75% ratio of that floaft. The average trading volume of NVAX on November 20, 2023 was 9.49M shares.
NVAX) stock’s latest price update
Novavax, Inc. (NASDAQ: NVAX)’s stock price has dropped by -1.72 in relation to previous closing price of 5.83. Nevertheless, the company has seen a loss of -8.17% in its stock price over the last five trading days. Investors Business Daily reported 2023-11-17 that Novavax stock is on the downswing again after the company cut its outlook for the year. Is NVAX stock a buy or a sell right now?
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with B. Riley Securities repeating the rating for NVAX by listing it as a “Buy.” The predicted price for NVAX in the upcoming period, according to B. Riley Securities is $15 based on the research report published on August 09, 2023 of the current year 2023.
NVAX Trading at -18.04% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.16% of loss for the given period.
Volatility was left at 6.48%, however, over the last 30 days, the volatility rate increased by 5.11%, as shares sank -10.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.12% lower at present.
During the last 5 trading sessions, NVAX fell by -8.17%, which changed the moving average for the period of 200-days by -52.29% in comparison to the 20-day moving average, which settled at $6.49. In addition, Novavax, Inc. saw -44.26% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NVAX starting from Glenn Gregory M, who purchase 1,000 shares at the price of $6.50 back on Mar 10. After this action, Glenn Gregory M now owns 14,473 shares of Novavax, Inc., valued at $6,500 using the latest closing price.
Glenn Gregory M, the President, R&D of Novavax, Inc., purchase 2,000 shares at $7.04 during a trade that took place back on Mar 07, which means that Glenn Gregory M is holding 13,473 shares at $14,088 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -32.53 for the present operating margin
- +54.46 for the gross margin
The net margin for Novavax, Inc. stands at -33.20.
When we switch over and look at the enterprise to sales, we see a ratio of -0.05, with the company’s debt to enterprise value settled at 8.42. The receivables turnover for the company is 7.38 and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.69.
In a nutshell, Novavax, Inc. (NVAX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.